BACKGROUND: To determine the risk of thyroid dysfunction and subsequent thyroid cancer among childhood acute lymphoblastic leukemia (ALL) survivors. PROCEDURE: Rates of self-reported thyroid dysfunction and thyroid cancer were determined among 3,579 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986, and compared with 3,846 siblings and population rates, respectively. RESULTS: The cumulative incidence of hypo- and hyperthyroidism among survivors 15 years following leukemia diagnosis was 1.6% (95% CI 1.1, 2.1) and 0.6% (95% CI 0.3, 1.1), respectively, both significantly increased compared with siblings. In multivariate analysis, survivors who received >or=20 Gy cranial radiotherapy plus any spinal radiotherapy had the highest risk of subsequent hypothyroidism (HR 8.3, 95% CI 3.3, 20.5) compared with those treated with chemotherapy alone. Craniospinal radiotherapy also was associated with an increased risk of subsequent hyperthyroidism (HR 6.1, 95% CI 1.1, 34.2) compared with chemotherapy alone, as well as an increased risk of subsequent thyroid cancers (SIR 30.3, 95% CI 14.5, 55.7) compared with population rates. In radiation dosimetry analysis, pituitary doses >or=20 Gy combined with thyroid doses >or=10 Gy were associated with hypothyroidism, whereas pituitary doses >or=20 Gy combined with thyroid doses >or=15 Gy were associated with hyperthyroidism. CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy. In these individuals, long-term surveillance is warranted as no obvious plateau in risk was seen, even after 25 years of follow-up. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: To determine the risk of thyroid dysfunction and subsequent thyroid cancer among childhood acute lymphoblastic leukemia (ALL) survivors. PROCEDURE: Rates of self-reported thyroid dysfunction and thyroid cancer were determined among 3,579 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986, and compared with 3,846 siblings and population rates, respectively. RESULTS: The cumulative incidence of hypo- and hyperthyroidism among survivors 15 years following leukemia diagnosis was 1.6% (95% CI 1.1, 2.1) and 0.6% (95% CI 0.3, 1.1), respectively, both significantly increased compared with siblings. In multivariate analysis, survivors who received >or=20 Gy cranial radiotherapy plus any spinal radiotherapy had the highest risk of subsequent hypothyroidism (HR 8.3, 95% CI 3.3, 20.5) compared with those treated with chemotherapy alone. Craniospinal radiotherapy also was associated with an increased risk of subsequent hyperthyroidism (HR 6.1, 95% CI 1.1, 34.2) compared with chemotherapy alone, as well as an increased risk of subsequent thyroid cancers (SIR 30.3, 95% CI 14.5, 55.7) compared with population rates. In radiation dosimetry analysis, pituitary doses >or=20 Gy combined with thyroid doses >or=10 Gy were associated with hypothyroidism, whereas pituitary doses >or=20 Gy combined with thyroid doses >or=15 Gy were associated with hyperthyroidism. CONCLUSIONS: The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy. In these individuals, long-term surveillance is warranted as no obvious plateau in risk was seen, even after 25 years of follow-up. (c) 2009 Wiley-Liss, Inc.
Authors: Suchitra Acharya; Kyriakie Sarafoglou; Michael LaQuaglia; Skyler Lindsley; William Gerald; Norma Wollner; Charlotte Tan; Charles Sklar Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: Hanneke M van Santen; Thomas Vulsma; Marcel G Dijkgraaf; Regje M E Blumer; Richard Heinen; Monique W M Jaspers; Maud M Geenen; Martin O Offringa; Jan J M de Vijlder; Cor van den Bos Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Peter D Inskip; Lene H S Veiga; Alina V Brenner; Alice J Sigurdson; Evgenia Ostroumova; Eric J Chow; Marilyn Stovall; Susan A Smith; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Charles A Sklar; Jay H Lubin Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-12 Impact factor: 7.038
Authors: Eric J Chow; Wei Liu; Kumar Srivastava; Wendy M Leisenring; Robert J Hayashi; Charles A Sklar; Marilyn Stovall; Leslie L Robison; K Scott Baker Journal: Pediatr Blood Cancer Date: 2012-05-24 Impact factor: 3.167
Authors: Peter D Inskip; Lene H S Veiga; Alina V Brenner; Alice J Sigurdson; Evgenia Ostroumova; Eric J Chow; Marilyn Stovall; Susan A Smith; Rita E Weathers; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Charles A Sklar; Jay H Lubin Journal: Radiat Res Date: 2018-05-15 Impact factor: 2.841
Authors: Susan R Rose; Vincent E Horne; Jonathan Howell; Sarah A Lawson; Meilan M Rutter; Gylynthia E Trotman; Sarah D Corathers Journal: Nat Rev Endocrinol Date: 2016-04-01 Impact factor: 43.330